高原 - 复旦大学

个人简介

高原，副研究员，医学博士，1995、1998年先后在沈阳药科大学获得药剂学学士和硕士学位，2009年毕业于第二军医大学，2010-2012先后在中科院药物所、University of Alberta开展博士后研究。曾在上药集团、第二军医大学附属长海医院从事新药研发与基础研究，也曾赴CDE进修，2017年加入复旦大学药学院。目前主持国家自然科学基金面上项目3项，在Nature Biotech, Theranostics, Pharmacol Res, Adv Mater等刊物发表Sci论文30余篇, 授权专利10项，主编专著4项，主持30多项新药研发转化。担任中国药学会药品安全评价专委会委员、上海市药理学会临床药理专委会委员、中国医药教育协会创新药物与临床评价专委会委员、世界中医药联合会儿童健康产品委员会理事等。获奖及荣誉 2005年度上海市“新长征突击手”

研究领域

肿瘤精准治疗临床大数据挖掘研究临床需求为导向的医学转化与药物研发

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

M Lv, J Chen, Y Peng, L Gong, F Han, J Guo, L Tian, Y Gao*. The global patent landscape of mRNA for diagnosis and therapy. Nature Biotech, 41:1193-1199 (2023) Wu Y, Xie H, Li Y, Bao X, Lu G, Wen J, Gao Y,* Li Y,* Zhang Z*. Nitric oxide-loaded bioinspired lipoprotein normalizes tumor vessels to improve intratumor delivery and chemotherapy of albumin-bound paclitaxel nanoparticles. Nano Letters, 23:939-947(2023) Y Wang, X Liu, L Gong, W Ding, W Hao, Y Peng, J Zhang, W Cai*, Y Gao*. Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics. Bri J Pharmacol. 180:2937-2955 (2023) Li J, Gong C, Chen X, Guo H, Tai Z, Ding N, Gao S*, Gao Y*. Biomimetic liposomal nanozymes improve breast cancer chemotherapy with enhanced penetration and alleviated hypoxia. J Nanobiotech, 21:123 (2023) Wang Y, Chen J, Gao Y*, Xu C*. Mechanisms of Enzalutamide Resistance and Therapeutic Strategies to Overcome it. Bri J Pharmacol. 178: 239–61 (2021) Wu W, Wang Y, Tang Z, Gao Y*, Huo Y*. Regulatory oversight of cell-based therapy in China: government’s efforts in patient access and therapeutic innovation. Pharmacol Res. 158: 104889 (2020) Wu W, Tang Z, Chen J, Gao Y*. Pediatric drug development in China: Reforms and challenges, Pharmacol Res, 148:104412 (2019) Wu W#, Huo Y#, Ding X, Gao Y*, Identification of the Risks in CAR T-Cell Therapy Clinical Trials in China: A Delphi Study. Ther. Adv. Med. Oncol. 12: 1–12 (2020) Chen J, Wu ZJ, Ding WH, Xiao CW, Gao S, Gao Y*, Cai W*. SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nano-system against bone metastatic castration-resistant prostate cancer. Theranostics 10: 1619-32 (2020) Gong C, Hu C, Gu F, Xia Q, Yao C, Zhang L, Qiang L, Gao S*, Gao Y*. Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment. J Control Release 266, 272-286 (2017)